| Not Yet Recruiting | Mass Balance Study of [14C] LPM3770164 in Healthy Participants NCT07516899 | Luye Pharma Group Ltd. | Phase 1 |
| Recruiting | Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease NCT07451613 | Leslie Thompson | Phase 1 / Phase 2 |
| Not Yet Recruiting | Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease NCT07409597 | University Hospital, Angers | N/A |
| Not Yet Recruiting | Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease NCT07513844 | First Affiliated Hospital of Fujian Medical University | N/A |
| Recruiting | A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Dis NCT07326709 | Novartis Pharmaceuticals | Phase 3 |
| Recruiting | iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009 NCT06634628 | CHDI Foundation, Inc. | EARLY_Phase 1 |
| Not Yet Recruiting | Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease NCT07315984 | BioSensics | — |
| Recruiting | Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Dise NCT07378644 | Skyhawk Therapeutics, Inc. | Phase 2 / Phase 3 |
| Recruiting | Evaluation of Three Tests to Assess Social Cognition in Huntington Disease NCT07253038 | Region Skane | — |
| Recruiting | Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3) NCT07213648 | University of Virginia | N/A |
| Recruiting | Home-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington' NCT06843252 | The University of Texas Health Science Center at San Antonio | N/A |
| Not Yet Recruiting | Transcranial Static Magnetic Stimulation (tSMS) in Huntington's Disease (HD) NCT06976983 | Neuromed IRCCS | N/A |
| Recruiting | Hinting Task for Huntington's Disease NCT06774443 | University Medical Center Groningen | — |
| Recruiting | Cognitive Assessment Tools for Huntington's Disease. NCT06546488 | Ohio State University | — |
| Recruiting | Digital Measures for Clinical Trial Endpoints in Huntington's Disease NCT07010705 | University of Rochester | — |
| Recruiting | Gut Microbiomes in HD NCT06448546 | University of Central Florida | — |
| Recruiting | Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease NCT06873334 | Skyhawk Therapeutics, Inc. | Phase 2 / Phase 3 |
| Recruiting | The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside Compared With Placebo in NCT06853743 | Oslo University Hospital | Phase 2 |
| Recruiting | A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease NCT06826612 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Recruiting | Early Biomarkers in Premanifest Huntington's Disease Gene Carriers: a Pilot Study NCT06626308 | University Hospital, Grenoble | N/A |
| Active Not Recruiting | A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease. NCT07339514 | ExoRNA Bioscience | Phase 1 / Phase 2 |
| Not Yet Recruiting | Huntington's Disease and Pain NCT06693466 | Leiden University Medical Center | — |
| Recruiting | Longitudinal SV2A and MRI in Premanifest HD NCT06626412 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Recruiting | Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD. NCT05360082 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Recruiting | Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders NCT06147414 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Study to Evaluate Music Therapy on Irritability and Impulsivity in Patients With Huntington's Disease (MUSIC-H NCT06414967 | Poitiers University Hospital | N/A |
| Recruiting | Gene Therapy Development and Validation for Huntington's Disease Fibro TG-HD NCT06444217 | University Hospital, Angers | N/A |
| Recruiting | Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers NCT06667414 | Hoffmann-La Roche | — |
| Completed | Time-Restricted Eating in Huntington's Disease: A Clinical Pilot Study NCT06490367 | Oregon Health and Science University | N/A |
| Completed | Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets NCT06474650 | Luye Pharma Group Ltd. | Phase 1 |
| Active Not Recruiting | The Safety and Tolerability Study With ER2001 Intravenous Injection Repetitive Treatment in Adults With Early NCT07344519 | ExoRNA Bioscience | EARLY_Phase 1 |
| Recruiting | Longitudinal Endpoint Assessment of Disease Burden in HD NCT06475898 | Huntington Study Group | — |
| Recruiting | FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases NCT06539169 | xCures | — |
| Unknown | Efficacy and Safety of NestaCell® in Huntington's Disease NCT06097780 | Azidus Brasil | Phase 3 |
| Recruiting | Huntington's Disease Biobank: Advancing Remote Monitoring and Deep Phenotyping NCT06941662 | Stanford University | — |
| Recruiting | A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers NCT05509153 | Western Sydney Local Health District | Phase 2 |
| Completed | Project AWARE 2.0 to Improve Awareness, Willingness and Ability for Research and Enrollment in Clinical Resear NCT06343220 | Huntington Study Group | — |
| Completed | Handgrip and Respiratory Dysfunction in HD Patients. NCT06585332 | General University Hospital, Prague | — |
| Recruiting | Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology NCT07136844 | Centre Hospitalier Universitaire de Liege | N/A |
| Recruiting | Innovative Imaging and Cognitive BIOmarkers to Predict Huntington's Disease Progression NCT05808153 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of MBF-015 in Huntington's Disease Patients NCT06469853 | Medibiofarma S.L. | Phase 2 |
| Not Yet Recruiting | Long Term Follow-up Grafted Huntington's Disease Patients NCT06194006 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects NCT06216054 | Luye Pharma Group Ltd. | Phase 1 |
| Recruiting | Extracellular Vesicles for HD NCT06082713 | University of Central Florida | — |
| Recruiting | Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers NCT05596760 | University of Washington | N/A |
| Active Not Recruiting | An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's NCT06254482 | Novartis Pharmaceuticals | Phase 2 |
| Recruiting | Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Hunting NCT05326451 | The University of Texas Health Science Center, Houston | N/A |
| Unknown | Impact of Apathy on Caregiving in HD. Version 1 NCT05913154 | University of East Anglia | — |
| Recruiting | Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease NCT04478734 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Phase 2 |
| Completed | The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's NCT06024265 | ExoRNA Bioscience | EARLY_Phase 1 |
| Recruiting | Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study NCT05773196 | Sanguine Biosciences | — |
| Unknown | Benchmarking Integrated Care for People Living With Huntington's Disease in England NCT05828992 | University of Southampton | — |
| Recruiting | A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD NCT05822908 | Vico Therapeutics B. V. | Phase 1 / Phase 2 |
| Active Not Recruiting | GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo i NCT05686551 | Hoffmann-La Roche | Phase 2 |
| Unknown | Striatum and Hippocampus on Different Time Scales NCT05943054 | Assistance Publique - Hôpitaux de Paris | N/A |
| Recruiting | NYSCF Scientific Discovery Biobank NCT06203106 | New York Stem Cell Foundation Research Institute | — |
| Active Not Recruiting | A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease NCT05541627 | Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio) | Phase 1 / Phase 2 |
| Unknown | A Pilot Study of Nutritional Status in Patients With Huntington's Disease NCT05668520 | University of Aberdeen | — |
| Completed | Development of the Virtual Unified Huntington's Disease Rating Scale NCT05748288 | Huntington Study Group | — |
| Completed | A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD) NCT05358717 | PTC Therapeutics | Phase 2 |
| Completed | 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease NCT05358821 | Supernus Pharmaceuticals, Inc. | Phase 2 |
| Completed | TEsting METformin Against Cognitive Decline in HD NCT04826692 | Instituto de Investigacion Sanitaria La Fe | Phase 3 |
| Active Not Recruiting | Huntington's Disease Young Adult Study 2.0 NCT06391619 | University College, London | — |
| Unknown | N- Homocysteinylated Huntingtin in Huntington's Disease NCT05225051 | Central Hospital, Nancy, France | N/A |
| Completed | Making HD Voices Heard NCT05268029 | Huntington Study Group | — |
| Completed | A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subj NCT05238701 | Luye Pharma Group Ltd. | Phase 1 |
| Terminated | Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HD NCT04301726 | Fundacion Huntington Puerto Rico | Phase 1 |
| Active Not Recruiting | Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register S NCT06209515 | Kuopio University Hospital | — |
| Completed | Measurement and Modification of Threat Interpretation Bias in Neurodegenerative Movement Disorders (Aims 2 & 3 NCT05126862 | University of Virginia | N/A |
| Active Not Recruiting | Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease NCT04713982 | Vanderbilt University Medical Center | Phase 2 / Phase 3 |
| Completed | Move to Improve: Telehealth Exercise to Music for HD NCT05270681 | Ohio State University | N/A |
| Completed | Efficacy of Cognitive Rehabilitation Using Virtual Reality and Computer-based Cognitive Stimulation on Cogniti NCT05769972 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | N/A |
| Active Not Recruiting | Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease NCT05243017 | UniQure Biopharma B.V. | Phase 1 / Phase 2 |
| Completed | Preparing for Prevention of Huntington's Disease (PREVENT-HD) NCT04818060 | University of Wisconsin, Madison | — |
| Unknown | Non-invasive Brain Stimulation in Huntington's Disease NCT04429230 | Western University, Canada | N/A |
| Completed | Study of WVE-003 in Patients With Huntington's Disease NCT05032196 | Wave Life Sciences Ltd. | Phase 1 / Phase 2 |
| Unknown | Clinicopathological MRI and CSF Correlates in Huntington's Disease. NCT05534139 | Leiden University Medical Center | — |
| Withdrawn | Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease NCT04885114 | Voyager Therapeutics | Phase 1 |
| Recruiting | IMarkHD: in Vivo Longitudinal Imaging of HD Pathology NCT03434548 | King's College London | — |
| Completed | Adapted Physical Activity Effect on Abilities and Quality of Life of Huntington Patients and Relatives During NCT04917133 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Energy Balance in Huntington's Disease. A Multidisciplinary Study Approach for a Complex Problem (BEHD-EM) NCT05250323 | Hospital Universitario de Burgos | — |
| Completed | Characterization and Quantification of Motor Speech Disorders in Huntington's Disease: Identification of Acous NCT04630574 | University Hospital, Bordeaux | — |
| Terminated | iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485 NCT03810898 | CHDI Foundation, Inc. | EARLY_Phase 1 |
| Completed | Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study NCT04421339 | The University of Texas Health Science Center, Houston | N/A |
| Completed | Complex Eye Movements in Parkinson's Disease and Related Movement Disorders NCT04925622 | Saccadous, Inc. | — |
| Unknown | Assessing the Symptomatic Benefit of Acoustic Slow Wave Enhancement in Parkinson Disease NCT04589182 | Christian Baumann | N/A |
| Completed | PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD NCT04556656 | Prilenia | Phase 3 |
| Unknown | NIPD on cffDNA for Triplet Repeat Diseases NCT04698551 | University Hospital, Montpellier | — |
| Unknown | Development of Assessments for Later Stage HD NCT04370470 | CHDI Foundation, Inc. | — |
| Completed | An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease NCT04514367 | Annexon, Inc. | Phase 2 |
| Completed | Risperidone for the Treatment of Huntington's Disease Involuntary Movements NCT04201834 | University of Rochester | Phase 2 |
| Completed | Dosimetry of [11C]CHDI-180R and [11C]CHDI-626. NCT05224115 | Universitaire Ziekenhuizen KU Leuven | — |
| Unknown | Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) - SHIELD HD NCT04406636 | CHDI Foundation, Inc. | — |
| Terminated | Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's NCT04617847 | Wave Life Sciences Ltd. | Phase 1 / Phase 2 |
| Unknown | Symptomatic Therapy for Patients With Huntington's Disease NCT04071639 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Recruiting | Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease NCT04012411 | University Hospital, Montpellier | N/A |
| Unknown | Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Pat NCT04219241 | Azidus Brasil | Phase 2 / Phase 3 |
| Unknown | Deep Brain Stimulation Treatment for Chorea in Huntington's Disease NCT04244513 | Beijing Municipal Administration of Hospitals | N/A |
| Completed | Synaptic Density and Progression of Huntington's Disease. NCT04701580 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Terminated | Couple and Spouse Caregiver in Huntington's Disease NCT04394767 | University Hospital, Lille | — |
| Completed | Clinical Study to Monitor Plasma Levels of 24OHC in Subject with HD NCT04257513 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | — |
| Terminated | Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's NCT04617860 | Wave Life Sciences Ltd. | Phase 1 / Phase 2 |
| Completed | Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease NCT03854019 | The University of Texas Health Science Center, Houston | Phase 3 |
| Completed | FuRST 2.0 Cognitive Pre-testing - Round 2 NCT03709173 | CHDI Foundation, Inc. | — |
| Terminated | Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease NCT03980938 | EIP Pharma Inc | Phase 2 |
| Unknown | Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders NCT04231487 | Rutgers, The State University of New Jersey | — |
| Terminated | Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products NCT03886753 | Children's Hospital of Philadelphia | — |
| Completed | An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntingto NCT03842969 | Hoffmann-La Roche | Phase 3 |
| Completed | Mitochondrial Biomarkers in Huntington's Disease NCT04515550 | University Hospitals Cleveland Medical Center | — |
| Completed | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Hunt NCT03787758 | Supernus Pharmaceuticals, Inc. | Phase 1 |
| Completed | Group Drum-Based Music Therapy Intervention for Parkinson's Disease/Huntington's Disease NCT05157074 | Johns Hopkins University | N/A |
| Unknown | Nilotinib in Huntington's Disease NCT03764215 | Georgetown University | Phase 1 |
| Completed | Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients NCT03417583 | Vanderbilt University Medical Center | N/A |
| Unknown | Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease NCT03599076 | BioSensics | — |
| Unknown | CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects NCT03713892 | Chong Kun Dang Pharmaceutical | Phase 1 |
| Unknown | PHysical Activity and Exercise Outcomes in Huntington's Disease NCT03344601 | Cardiff University | N/A |
| Completed | Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease NCT03252535 | Azidus Brasil | Phase 2 |
| Unknown | Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease NCT02728115 | Azidus Brasil | Phase 1 |
| Completed | Is Caffeine an Environmental Modifier in Huntington's Disease? NCT03034122 | University Hospital, Lille | — |
| Unknown | Metabolomic Study in Huntington's Disease (METABO-HD) NCT03296176 | University Hospital, Angers | N/A |
| Completed | Genetic Risk: Whether, When, and How to Tell Adolescents NCT03421327 | Johns Hopkins University | — |
| Recruiting | Retinal Imaging in Neurodegenerative Disease NCT03233646 | Duke University | — |
| Completed | Decoding Presymptomatic White Matter Changes in Huntington Disease NCT03193099 | Institut National de la Santé Et de la Recherche Médicale, France | N/A |
| Completed | Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease NCT03515213 | University of California, Irvine | Phase 2 |
| Terminated | Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurologica NCT03052712 | Centre Hospitalier Universitaire, Amiens | N/A |
| Unknown | Beta Testing of a New Assessment in Huntington's Disease (HD) NCT03119246 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Measuring Cortisol Levels in Persons With Parkinson's (PD) NCT02727270 | Oregon Health and Science University | — |
| Recruiting | Gait Analysis in Neurological Disease NCT02994719 | Beth Israel Deaconess Medical Center | — |
| Terminated | Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in NCT02907294 | Palobiofarma SL | Phase 1 |
| Completed | Resveratrol and Huntington Disease NCT02336633 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Dis NCT02453061 | Institut National de la Santé Et de la Recherche Médicale, France | Phase 2 |
| Completed | A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease NCT02464293 | Lancaster University | N/A |
| Withdrawn | Characterization of the Profile of Dysarthria in Huntington's Disease, Using the Clinical Evaluation Battery o NCT03142217 | Centre Hospitalier Universitaire, Amiens | N/A |
| Unknown | Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chore NCT01834053 | Chaitanya Hospital, Pune | Phase 1 / Phase 2 |
| Completed | Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD) NCT02535884 | Heinrich-Heine University, Duesseldorf | N/A |
| Terminated | Behavioural Problems in Huntington Disease : Analysis and Enhancement of Caregiver and Patient Experience NCT02218567 | University Hospital, Angers | N/A |
| Unknown | Feasibility of a Video-oculography in Patients With Huntington's Disease VOG-HD Study NCT02563418 | University Hospital, Angers | N/A |
| Completed | Accelerated Diffusion MRI for Diagnosis of Hungtington Disease NCT01884181 | Wang . Jiun-Jie | — |
| Completed | A Pre-Cellular Therapy Observational Study in Early Huntington's Disease NCT01937923 | University of California, Davis | — |
| Completed | Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington NCT01882062 | Institut National de la Santé Et de la Recherche Médicale, France | Phase 2 |
| Completed | Dance and Huntington Disease NCT01842919 | Institut National de la Santé Et de la Recherche Médicale, France | N/A |
| Completed | Effect of Tetrabenazine on Stroop Interference in HD NCT01834911 | New York Medical College | Phase 4 |
| Completed | Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease NCT02268617 | Ohio State University | N/A |
| Completed | Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrom NCT02819700 | Centre Hospitalier Universitaire, Amiens | — |
| Completed | Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disea NCT01696708 | Institut National de la Santé Et de la Recherche Médicale, France | N/A |
| Completed | Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease NCT01590888 | Prana Biotechnology Limited | Phase 2 |
| Completed | Evaluating the Relationship of Morphine Consumption and Pain-related Molecules in Hepatic Surgical Patients NCT01919034 | National Cheng-Kung University Hospital | — |
| Terminated | Biological Sample Collection for Research and Biobanking NCT04270604 | New York Stem Cell Foundation Research Institute | — |
| Completed | A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodyn NCT01573819 | GlaxoSmithKline | Phase 1 |
| Completed | Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inh NCT01602900 | GlaxoSmithKline | Phase 1 |
| Completed | A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease NCT01458470 | University of British Columbia | Phase 2 |
| Completed | Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study) NCT01357681 | Charite University, Berlin, Germany | Phase 2 |
| Completed | Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm NCT02814201 | Centre Hospitalier Universitaire, Amiens | — |
| Completed | 31P-MRS and Huntington Disease NCT01359774 | Institut National de la Santé Et de la Recherche Médicale, France | N/A |
| Completed | Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease NCT01306929 | Prilenia | Phase 2 |
| Completed | An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196 NCT01485952 | Siena Biotech S.p.A. | Phase 1 |
| Terminated | An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntingt NCT01085266 | Medivation, Inc. | Phase 3 |
| Completed | A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebo NCT00988624 | Pfizer | Phase 1 |
| Completed | Bioavailability of Ubiquinol in Huntington Disease NCT00980694 | University of Rochester | Phase 1 |
| Completed | Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects NCT00970229 | Institute for Neurodegenerative Disorders | Phase 1 |
| Completed | A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease NCT00920946 | Medivation, Inc. | Phase 3 |
| Completed | Assessment of Social-emotional Functioning in Neurological Diseases NCT01339130 | Centre Hospitalier Universitaire, Amiens | N/A |
| Unknown | Study of Huntington Patients in Connection With European Huntington's Disease Network (EHDN) NCT01554033 | Seoul National University Hospital | — |
| Completed | Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride NCT00632645 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions NCT00870974 | Institute for Neurodegenerative Disorders | Phase 1 |
| Completed | Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects NCT00831506 | Pfizer | Phase 1 |
| Completed | A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan NCT00788047 | Pfizer | Phase 1 |
| Completed | A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease NCT00724048 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 |
| Unknown | Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD) NCT00675077 | GAAD Medical Research Institute Inc. | Phase 1 |
| Completed | Creatine Safety and Tolerability in Premanifest HD: PRECREST NCT00592995 | Massachusetts General Hospital | Phase 2 |
| Completed | Research of Biomarkers in Parkinson Disease NCT00465790 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Completed | Making Sense of a Positive Genetic Test Result for Huntington Disease NCT00539747 | National Human Genome Research Institute (NHGRI) | — |
| Completed | Memory Disorders Registry NCT00654563 | Cedars-Sinai Medical Center | — |
| Unknown | Ursodiol in Huntington's Disease NCT00514774 | Oregon Health and Science University | Phase 1 |
| Completed | Pilot Study of Minocycline in Huntington's Disease NCT00277355 | Merit Cudkowicz | Phase 2 / Phase 3 |
| Unknown | Cooperative Huntington's Observational Research Trial NCT00313495 | HP Therapeutics Foundation | — |
| Completed | Atomoxetine and Huntington's Disease NCT00368849 | University of Iowa | Phase 2 |
| Completed | Citalopram to Enhance Cognition in HD NCT00271596 | University of Iowa | Phase 2 |
| Completed | TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease NCT00146211 | Amarin Neuroscience Ltd | Phase 3 |
| Completed | REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN) NCT01590589 | European Huntington's Disease Network | — |
| Unknown | Study of Biomarkers That Predict the Evolution of Huntington's Disease NCT01412125 | Assistance Publique - Hôpitaux de Paris | — |
| Active Not Recruiting | Neurobiological Predictors of Huntington's Disease (PREDICT-HD) NCT00051324 | Jordan Schultz | — |
| Completed | MIG-HD: Multicentric Intracerebral Grafting in Huntington's Disease NCT00190450 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | Family Health After Predictive Huntington Disease (HD) Testing NCT00075140 | National Institute of Nursing Research (NINR) | — |
| Completed | Riluzole in Huntington's Disease NCT00277602 | Sanofi | Phase 3 |
| Completed | Prospective Huntington At Risk Observational Study NCT00052143 | Huntington Study Group | — |